Arena Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARNA research report →
Companywww.arenapharm.com
Arena Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial.
- CEO
- Amit Munshi
- IPO
- 2000
- Employees
- 448
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -8.82
- P/S
- 0.00
- P/B
- 8.13
- EV/EBITDA
- 0.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1133840.74%
- Net Margin
- -1149244.44%
- ROE
- -70.77%
- ROIC
- -84.63%
Growth & Income
- Revenue
- $54.00K · -83.07%
- Net Income
- $-620,592,000 · -53.33%
- EPS
- $-11.33 · -53.32%
- Op Income
- $-612,274,000
- FCF YoY
- -47.78%
Performance & Tape
- 52W High
- $100.00
- 52W Low
- $45.50
- 50D MA
- $93.48
- 200D MA
- $70.91
- Beta
- 0.55
- Avg Volume
- 1.47M
Get TickerSpark's AI analysis on ARNA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 11, 22 | Nova Tina Susan | other | 17,776 |
| Mar 11, 22 | Nova Tina Susan | sell | 15,000 |
| Mar 11, 22 | Nova Tina Susan | sell | 7,202 |
| Mar 11, 22 | Nova Tina Susan | other | 3,067 |
| Mar 11, 22 | Nova Tina Susan | sell | 5,000 |
| Mar 11, 22 | Nova Tina Susan | sell | 5,000 |
| Mar 11, 22 | Nova Tina Susan | sell | 5,000 |
| Mar 11, 22 | Nova Tina Susan | sell | 4,800 |
| Mar 11, 22 | FETZER OLIVER | other | 1,525 |
| Mar 11, 22 | FETZER OLIVER | other | 8,167 |
Our ARNA Coverage
We haven't published any research on ARNA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARNA Report →